{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:35:45Z","timestamp":1760574945039,"version":"build-2065373602"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Key Research Center Project of Medical Imaging","award":["2023ZZ2006"],"award-info":[{"award-number":["2023ZZ2006"]}]},{"name":"Shanghai Municipal Strengthening Public Health System Construction","award":["GWVI-11.1-40"],"award-info":[{"award-number":["GWVI-11.1-40"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multiple myeloma (MM) is a heterogeneous malignancy with prognosis significantly affected by high-risk cytogenetic abnormalities (HRCAs). Traditional detection using fluorescence in situ hybridisation is invasive and limited in capturing disease heterogeneity. We aimed to develop and validate radiomics model based on pretreatment [18F] fluoro-deoxyglucose (FDG) positron emission tomography\/computed tomographic (18F-FDG PET\/CT) imaging to non-invasively predict HRCAs in newly diagnosed MM patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 42 candidate models, the Decision Tree classifier utilizing PET active lesions features demonstrated optimal performance in the validation cohort, exhibiting excellent predictive ability (Area Under the Curve (AUC)\u2009=\u20090.89), significantly outperforming the PET metrics model (AUC\u2009=\u20090.84) and clinical model (AUC\u2009=\u20090.74). SHapley Additive exPlanations analysis identified the PET-derived feature as the most important contributor to the model\u2019s predictive capacity. The model stratified patients into high-risk and low-risk groups, with the high-risk group exhibiting significantly worse PFS and OS (median PFS: high-risk 24.5 months vs. low-risk 29 months; <jats:italic>p<\/jats:italic>\u2009=\u20090.0360; median OS: high-risk 33.5 months vs. low-risk 50 months; <jats:italic>p<\/jats:italic>\u2009=\u20090.0023).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>As a non-invasive imaging biomarker, PET\/CT radiomics holds potential for predicting high-risk cytogenetic status and facilitating patient prognosis stratification Further large-scale, multi-center prospective validations are essential to confirm its utility for personalized therapeutic decision-making in MM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13550-025-01321-8","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:08:45Z","timestamp":1760522925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A feasibility study of [18F] FDG PET\/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma"],"prefix":"10.1186","volume":"15","author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunkang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"9","key":"1321_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"issue":"5","key":"1321_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"issue":"1","key":"1321_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"1321_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217440","volume":"611","author":"X Dou","year":"2025","unstructured":"Dou X, Duan G, Zhong Y, Liu Y, Peng N, Wen L, et al. The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050. Cancer Lett. 2025;611:217440. https:\/\/doi.org\/10.1016\/j.canlet.2025.217440.","journal-title":"Cancer Lett"},{"issue":"8","key":"1321_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3760\/cma.j.issn.0253-2727.2019.08.004","volume":"40","author":"XL Liu","year":"2019","unstructured":"Liu XL, Bai J, Fan HQ, Yang YP, Yue TT, Zhang Y, et al. :[Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(8):644\u20139. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.08.004.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"7","key":"1321_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409\u201321. https:\/\/doi.org\/10.1038\/s41571-018-0018-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1321_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3324\/haematol.2021.280566","volume":"108","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, et al. :Heterogeneity in long-term outcomes for patients with revised international staging system stage II, newly diagnosed multiple myeloma. Haematologica. 2023;108(5):1374\u201384. https:\/\/doi.org\/10.3324\/haematol.2021.280566.","journal-title":"Haematologica"},{"issue":"11","key":"1321_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/jco.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42(11):1229\u201340. https:\/\/doi.org\/10.1200\/jco.23.01277.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1321_CR9","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/jco.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1321_CR10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56(9):1878\u201389. https:\/\/doi.org\/10.1038\/s41588-024-01853-0.","journal-title":"Nat Genet"},{"issue":"26","key":"1321_CR11","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137(26):3616\u201328. https:\/\/doi.org\/10.1182\/blood.2020008787.","journal-title":"Blood"},{"issue":"10272","key":"1321_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C. Yong kl:multiple myeloma. Lancet (London England). 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5.","journal-title":"Lancet (London England)"},{"issue":"24","key":"1321_CR13","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955\u201362. https:\/\/doi.org\/10.1182\/blood-2016-01-631200.","journal-title":"Blood"},{"issue":"1","key":"1321_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","volume":"52","author":"C Nanni","year":"2024","unstructured":"Nanni C, Deroose CM, Balogova S, Lapa C, Withofs N, Subesinghe M, et al. EANM guidelines on the use of [(18)F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. Eur J Nucl Med Mol Imaging. 2024;52(1):171\u201392. https:\/\/doi.org\/10.1007\/s00259-024-06858-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1321_CR15","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/s1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18(4):e206\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1321_CR16","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/s1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. :International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302\u201312. https:\/\/doi.org\/10.1016\/s1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1321_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","volume":"64","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2023","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Jamet B, Bezzi D, Zamagni E, Moreau P, Nanni C. New developments in myelomatreatment and response assessment. J Nucl Med. 2023;64(9):1331\u201343. https:\/\/doi.org\/10.2967\/jnumed.122.264972.","journal-title":"J Nucl Med"},{"issue":"1","key":"1321_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01113-6","volume":"14","author":"S Marchiori","year":"2024","unstructured":"Marchiori S, Cousin F, Papadopoulos I, Bernard C, Thys M, De Prijck B, et al. Prognostic value of visual impetus criteria and metabolic tumor burden at baseline [(18)F]FDG PET\/CT in patients with newly diagnosed multiple myeloma. EJNMMI Res. 2024;14(1):51. https:\/\/doi.org\/10.1186\/s13550-024-01113-6.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1321_CR19","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00259-024-06668-z","volume":"51","author":"C Sachpekidis","year":"2024","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Mai EK, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [(18)F]FDG PET\/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024;51(8):2293\u2013307. https:\/\/doi.org\/10.1007\/s00259-024-06668-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1321_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07219-w","author":"M Zhang","year":"2025","unstructured":"Zhang M, Cai T, Jin S, Huang X, Gao Y, Chen X, et al. Prognostic value of [(18)F]fluorodeoxyglucose-PET\/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07219-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1321_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1321_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41698-024-00656-0","volume":"8","author":"H Paverd","year":"2024","unstructured":"Paverd H, Zormpas-Petridis K, Clayton H, Burge S, Crispin-Ortuzar M. Radiology and multi-scale data integration for precision oncology. NPJ Precis Oncol. 2024;8(1):158. https:\/\/doi.org\/10.1038\/s41698-024-00656-0.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"1321_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40644-024-00670-2","volume":"24","author":"H Zhao","year":"2024","unstructured":"Zhao H, Su Y, Wang Y, Lyu Z, Xu P, Gu W, et al. Using tumor habitat-derived radiomic analysis during pretreatment (18)F-FDG PET for predicting KRAS\/NRAS\/BRAF mutations in colorectal cancer. Cancer Imaging. 2024;24(1):26. https:\/\/doi.org\/10.1186\/s40644-024-00670-2.","journal-title":"Cancer Imaging"},{"key":"1321_CR24","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.11.005","author":"C Sachpekidis","year":"2024","unstructured":"Sachpekidis C, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A. Radiomics and artificial intelligence landscape for [(18)F]FDG PET\/CT in multiple myeloma. Semin Nucl Med. 2024. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.11.005.","journal-title":"Semin Nucl Med"},{"issue":"4","key":"1321_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.62347\/nllv9295","volume":"14","author":"Y Liu","year":"2024","unstructured":"Liu Y, Huang W, Yang Y, Cai W. Sun z:recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma. Am J Nucl Med Mol Imaging. 2024;14(4):208\u201329. https:\/\/doi.org\/10.62347\/nllv9295.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1321_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247669","author":"L Manco","year":"2023","unstructured":"Manco L, Albano D, Urso L, Arnaboldi M, Castellani M, Florimonte L, et al. Positron emission Tomography-derived radiomics and artificial intelligence in multiple myeloma: state-of-the-art. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12247669.","journal-title":"J Clin Med"},{"issue":"9","key":"1321_CR27","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s11547-021-01388-y","volume":"126","author":"J Liu","year":"2021","unstructured":"Liu J, Wang C, Guo W, Zeng P, Liu Y, Lang N, et al. A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma. Radiol Med. 2021;126(9):1226\u201335. https:\/\/doi.org\/10.1007\/s11547-021-01388-y.","journal-title":"Radiol Med"},{"key":"1321_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100617","volume":"47","author":"S Liu","year":"2024","unstructured":"Liu S, Pan H, Li S, Li Z, Sun J, Ren T, et al. Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging. J Bone Oncol. 2024;47:100617. https:\/\/doi.org\/10.1016\/j.jbo.2024.100617.","journal-title":"J Bone Oncol"},{"issue":"1","key":"1321_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13244-024-01672-1","volume":"15","author":"T Van Den Berghe","year":"2024","unstructured":"Van Den Berghe T, Verberckmoes B, Kint N, Wallaert S, De Vos N, Algoet C, et al. Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging. Insights into Imaging. 2024;15(1):106. https:\/\/doi.org\/10.1186\/s13244-024-01672-1.","journal-title":"Insights into Imaging"},{"issue":"4","key":"1321_CR30","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1016\/j.crad.2023.12.014","volume":"79","author":"X Xiong","year":"2024","unstructured":"Xiong X, Wang J, Hao Z, Fan X, Jiang N, Qian X, et al. :MRI-based bone marrow radiomics for predicting cytogenetic abnormalities in multiple myeloma. Clin Radiol. 2024;79(4):e491\u20139. https:\/\/doi.org\/10.1016\/j.crad.2023.12.014.","journal-title":"Clin Radiol"},{"issue":"1","key":"1321_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268. https:\/\/doi.org\/10.1038\/s41467-017-00296-y.","journal-title":"Nat Commun"},{"issue":"4","key":"1321_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.118.223495","volume":"60","author":"CF Uribe","year":"2019","unstructured":"Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, B\u00e9nard F, et al. :Machine learning in nuclear medicine: part 1-Introduction. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60(4):451\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.223495.","journal-title":"Soc Nuclear Med"},{"issue":"2","key":"1321_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1321_CR34","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. :International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1321_CR35","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.Can-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to Decode the radiographic phenotype. Cancer Res. 2017;77(21):e104\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0339.","journal-title":"Cancer Res"},{"key":"1321_CR36","unstructured":"Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. In: Proceedings of the 31st International Conference on Neural Information Processing Systems. Long Beach, California, USA: Curran Associates Inc.; 2017: 4768\u20134777."},{"issue":"4","key":"1321_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cpet.2021.06.007","volume":"16","author":"F Orlhac","year":"2021","unstructured":"Orlhac F, Nioche C, Klyuzhin I, Rahmim A, Buvat I. Radiomics in PET imaging:: a practical guide for newcomers. PET Clin. 2021;16(4):597\u2013612. https:\/\/doi.org\/10.1016\/j.cpet.2021.06.007.","journal-title":"PET Clin"},{"key":"1321_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010264","author":"V Rodr\u00edguez-Laval","year":"2024","unstructured":"Rodr\u00edguez-Laval V, Lumbreras-Fern\u00e1ndez B, Aguado-Bueno B, G\u00f3mez-Le\u00f3n N. Imaging of multiple myeloma: present and future. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13010264.","journal-title":"J Clin Med"},{"issue":"1","key":"1321_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","volume":"11","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Merz M, Raab MS, Bertsch U, Weru V, Kopp-Schneider A, et al. The prognostic significance of [(18)F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11(1):100. https:\/\/doi.org\/10.1186\/s13550-021-00846-y.","journal-title":"EJNMMI Res"},{"issue":"3","key":"1321_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1053\/j.semnuclmed.2022.10.008","volume":"53","author":"D Bezzi","year":"2023","unstructured":"Bezzi D, Ambrosini V, Nanni C. Clinical value of FDG-PET\/CT in multiple myeloma: an update. Semin Nucl Med. 2023;53(3):352\u201370. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.008.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"1321_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1148\/radiol.2021202553","volume":"298","author":"MR Tomaszewski","year":"2021","unstructured":"Tomaszewski MR, Gillies RJ. The biological meaning of radiomic features. Radiology. 2021;298(3):505\u201316. https:\/\/doi.org\/10.1148\/radiol.2021202553.","journal-title":"Radiology"},{"issue":"4","key":"1321_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11(4):83. https:\/\/doi.org\/10.1038\/s41408-021-00474-8.","journal-title":"Blood Cancer J"},{"key":"1321_CR43","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF et al. :International myeloma society\/international myeloma working group consensus recommendations on the definition of High-Risk multiple myeloma. J Clin Oncology: Official J Am Soc Clin Oncol 2025:Jco240189310.1200\/jco-24-01893"},{"issue":"9","key":"1321_CR44","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/tomography10090107","volume":"10","author":"JA Fajemisin","year":"2024","unstructured":"Fajemisin JA, Gonzalez G, Rosenberg SA, Ullah G, Redler G, Latifi K, et al. Magnetic resonance-guided cancer therapy radiomics and machine learning models for response prediction. Tomography. 2024;10(9):1439\u201354. https:\/\/doi.org\/10.3390\/tomography10090107.","journal-title":"Tomography"},{"key":"1321_CR45","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","volume":"5","author":"HJ Aerts","year":"2014","unstructured":"Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. https:\/\/doi.org\/10.1038\/ncomms5006.","journal-title":"Nat Commun"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01321-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:08:51Z","timestamp":1760522931000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01321-8","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective study was conducted at Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital, approved by the Institutional Ethics Committee (Approval No:2024-KY-266(K)) with waived informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This retrospective study utilized anonymized patient data and was granted a waiver of informed consent by the Institutional Ethics Committee (Approval No:2024-KY-266(K)). All data were de-identified prior to analysis to ensure participant confidentiality.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}